A study published in the scientific journal Nature showed that the application of a booster dose of Pfizer’s Covid-19 vaccine six months after immunization with two doses of Coronavac confers an efficacy of 92.7% against the disease. Already against severe cases of the new coronavirus, protection rises to 97.3%.
The research was carried out only with Brazilians, and analyzed data from about 14 million people, 913,052 of whom were immunized with Coronavac, manufactured by the Butantan Institute and the Chinese pharmaceutical company Sinovac. The results were published on Wednesday (9).
In addition, the study reinforced the importance of vaccination against Covid-19 and found that people vaccinated with two doses of Coronavac had 55% more protection against infection with the disease than those not immunized. Regarding severe cases, the effectiveness of vaccinated reached 82.1%.
In these cases, however, it was found that the efficacy drops to 34.7% and 72.5% in severe cases after 180 days (6 months) of application of the second dose. In this way, the researchers concluded the importance of strengthening vaccination against Covid-19.
The National Health Surveillance Agency (Anvisa) reinforces that vaccines against the new coronavirus approved by the agency for application in Brazil are effective and safe.
Coronavac and adverse effects
Another research, carried out in Hong Kong and published in the journal Vaccines, showed that people vaccinated with Coronavac are 83% less likely to have adverse reactions than those who received immunizations using messenger RNA technology.
The work was conducted between February and July 2021 by researchers from the University of Hong Kong, the University of London, the Department of Government Health and the Science and Technology Park, and involved 1,129 volunteers who received Coronavac, with an average age of 46. years, and 969 people who received Pfizer’s messenger RNA vaccine, with an average age of 43 years.
Research participants received follow-up for 14 days after each dose was administered, and answered a questionnaire about possible adverse reactions.
“Adjusted analysis suggests that compared to Comirnaty [nome oficial da vacina da Pfizer]CoronaVac is associated with an 83% lower chance of causing any adverse reactions and a 76% lower chance of systemic adverse reactions,” the study described.
Source: CNN Brasil
